May. 13 at 9:22 AM
$AXSM I listened to yesterday's conference and what I'd like to share what I found interesting frim the transcript: "So maybe just kind of summarizing it from a quantitative perspective, we are currently at 0.2% of the total antidepressant market, annualizing over
$600 million. We're at 0.3% of the NBRx market. So NBRx obviously being a leading indicator of where we expect to be from the [indiscernible], and that number is anticipated to grow as we further invest in the field force as we further invest into the commercialization of the product."
I think this explains the raise to 8bn peak sales guidance for Auvelity as a conservative estimate. We barely penetrated the MDD market and are already at 600 million revenue.
